Pharsight

Axumin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5808146 BLUE EARTH Amino acid analogs for tumor imaging
Nov, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387266 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10010632 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10953112 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10967077 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10124079 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10933147 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

US10716868 BLUE EARTH Imaging of metastatic or recurrent cancer
Dec, 2035

(11 years from now)

Axumin is owned by Blue Earth.

Axumin contains Fluciclovine F-18.

Axumin has a total of 8 drug patents out of which 1 drug patent has expired.

Expired drug patents of Axumin are:

  • US5808146

Axumin was authorised for market use on 27 May, 2016.

Axumin is available in solution;intravenous dosage forms.

Axumin can be used as method of diagnosing tumors using positron emission tomography, positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment.

Drug patent challenges can be filed against Axumin from 27 May, 2020.

The generics of Axumin are possible to be released after 30 December, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate speci...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AXUMIN family patents

Family Patents